Minomic forges prostate cancer partnership
Minomic International has entered a partnership with US-based Catalent Pharma Solutions aimed at developing a potential new treatment for prostate cancer.
The companies have agreed to jointly develop Minomic’s MIL-38 - the antibody drug conjugate used in its prostate cancer screening test MiSat - into a potential therapeutic product.
Catalent will use its GPEx cell line retrovector to redesign MIL-38 as a therapeutic antibody for a clinical study, which will commence as early as the second quarter of 2015.
Minomic CEO Dr Brad Walsh said preclinical trials of MIL-38 as a therapeutic have been “extremely promising. Our ultimate aim is to leverage our existing technology to not only screen for prostate cancer, but to treat it.”
Minomic is gearing up for a 1200-sample trial of the MiSat diagnostic test in the US that will form part of the company’s submission with the US FDA and be used to help market the test to potential partners or licensees.
Previous studies suggest that MiSat is almost twice as specific as the current standard prostate cancer screening test, PSA, which is controversial due to its high false-positive rate.
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
